Personalizing metastatic prostate cancer treatment: New VA findings and Rutgers editorial
A comprehensive VA study involving 5,135 veterans reveals that enzalutamide and abiraterone offer similar survival benefits for metastatic prostate cancer, with enzalutamide showing slight advantages in patients over 75, aiding personalized treatment decisions.
New findings from Veterans Affairs (VA) could aid clinical decision-making for metastatic prostate cancer patients, according to an accompanying editorial from a Rutgers expert. Details of the study and editorial are reported in an article by Andrew Smith.
The researchers compared common metastatic prostate cancer treatments, enzalutamide and abiraterone, in 5,135 veterans. All participants had been treated between 2020-2023 via the VA health system.
Key findings:
Both drugs produced similar survival outcomes
Enzalutamide may be slightly more beneficial for survival in patients aged 75 and older
This is the largest study to date comparing both drugs in prostate cancer patients in the metastatic castration-sensitive setting
Wadih Arap, chief of oncology/hematology at Rutgers New Jersey Medical School wrote the study’s accompanying editorial. He emphasized that these findings will help clinicians personalize treatment for prostate cancer patients with real-world evidence.
